Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H P Hofmann

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
Arzneimittel-Forschung|September 1, 1988
[Pharmacological characterization of the new highly potent beta-adrenergic receptor blocker soquinolol]J Gries, L Unger, H Einig, et al.
The European Journal of Neuroscience|February 13, 1999
A new pyrrolyl-quinoxalinedione series of non-NMDA glutamate receptor antagonists: pharmacological characterization and comparison with NBQX and valproate in the kindling model of epilepsyW Löscher, H Lehmann, B Behl, et al.
British Journal of Cancer|July 12, 2007
High expression of RelA/p65 is associated with activation of nuclear factor-kappaB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosisW Weichert, M Boehm, V Gekeler, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
Arzneimittel-Forschung|September 1, 1988
[Pharmacological characterization of the new highly potent beta-adrenergic receptor blocker soquinolol]J Gries, L Unger, H Einig, et al.
The European Journal of Neuroscience|February 13, 1999
A new pyrrolyl-quinoxalinedione series of non-NMDA glutamate receptor antagonists: pharmacological characterization and comparison with NBQX and valproate in the kindling model of epilepsyW Löscher, H Lehmann, B Behl, et al.
British Journal of Cancer|July 12, 2007
High expression of RelA/p65 is associated with activation of nuclear factor-kappaB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosisW Weichert, M Boehm, V Gekeler, et al.
Pageof 4